Immunotherapy is rapidly emerging as a cancer treatment with high potential. Recent clinical trials with anti-CTLA-4 and anti–PD-1/PD-L1 antibodies (mAbs) suggest that targeting multiple immunosuppressive pathways may significantly improve patient survival. The generation of adenosine by CD73 also suppresses antitumor immune responses through the activation of A2A receptors on T cells and natural killer (NK) cells. We sought to determine whether blockade of A2A receptors could enhance the efficacy of anti–PD-1 mAb. The expression of CD73 by tumor cells limited the efficacy of anti–PD-1 mAb in two tumor models, and this was alleviated with concomitant treatment with an A2A adenosine receptor antagonist. The blockade of PD-1 enhanced A2A receptor expression on tumor-infiltrating CD8+ T cells, making them more susceptible to A2A-mediated suppression. Thus, dual blockade of PD-1 and A2A significantly enhanced the expression of IFNγ and Granzyme B by tumor-infiltrating CD8+ T cells and, accordingly, increased growth inhibition of CD73+ tumors and survival of mice. The results of our study indicate that CD73 expression may constitute a potential biomarker for the efficacy of anti–PD-1 mAb in patients with cancer and that the efficacy of anti–PD-1 mAb can be significantly enhanced by A2A antagonists. We have therefore revealed a potentially novel biomarker for the efficacy of anti–PD-1 that warrants further investigation in patients. Because our studies used SYN-115, a drug that has already undergone phase IIb testing in Parkinson disease, our findings have immediate translational relevance for patients with cancer. Cancer Immunol Res; 3(5); 506–17. ©2015 AACR.
The importance of the immune system in the control of cancers is increasingly being recognized. Tumors use multiple inhibitory pathways to suppress the immune response and thus lead to “immune escape” (1). The clinical success of therapies that block these inhibitory pathways, such as anti–PD-1 (2) and anti-CTLA-4 (3) mAbs, underlines the potential of immunotherapy to treat cancer in a more specific fashion with fewer adverse events than with conventional cancer therapies.
One mechanism of tumor-induced immune suppression is the generation of adenosine by the ectoenzyme CD73 (4). In terms of the generation of adenosine, CD73 sits downstream of the ectoenzyme CD39 that catalyzes the degradation of ATP into AMP via the intermediate ADP. AMP then acts as a substrate for CD73, resulting in the production of immunosuppressive adenosine (4). A major enzyme for the degradation of adenosine is adenosine deaminase (ADA). ADA can be expressed on the cell surface when bound to CD26; however, CD26 expression is reduced on tumor cells (5). Thus, the tumor microenvironment contains concentrations of adenosine sufficient to inhibit antitumor T-cell responses (6).
CD73 is endogenously expressed on epithelial cells, endothelial cells, and some immune subsets, and its expression has also been observed in several cancer types, including colon cancer, melanoma, breast cancer, ovarian cancer, and leukemia (4). Notably, the expression of CD73 by tumor cells in patients with triple-negative breast cancer correlates with an increased risk of metastasis and consequently poor patient outcomes (7, 8). The drivers of CD73 expression within the tumor microenvironment include hypoxia, type I IFNs, TNFα, IL1β, prostaglandin (PG)E2, and TGFβ (4). Moreover, it has been shown that certain chemotherapies, including anthracyclines, can drive CD73 expression, contributing to chemoresistance of tumor cells (8). The protumoral effect of CD73 has been validated in preclinical models showing that targeting CD73 with a mAb can reduce primary tumor growth and metastasis (9). Moreover, anti-CD73 has been shown to enhance the efficacy of chemotherapy and other immunotherapies (8, 10).
Although targeting CD73 directly has shown great therapeutic promise, there is as yet no clinical development of anti-CD73 mAbs. However, because the immunosuppressive effects of CD73 are mediated by adenosine, targeting the downstream adenosine receptors has high translational potential. Activation of A2A and A2B receptors is known to suppress multiple immune cells, including the proliferation, cytokine production, and cytotoxicity of T cells (4, 11). Notably, in the context of cancer, activation of either A2A or A2B receptors has been shown to reduce antitumor immunity (6, 12, 13) and enhance the metastasis of CD73+ tumors (14). Moreover, antagonists targeting the A2A and A2B receptors have undergone clinical trials for other indications and have shown a good safety profile (15, 16).
In this study, we investigated whether blockade of A2A receptors could enhance the efficacy of anti–PD-1. Because PD-1 blockade is known to enhance T-lymphocyte function, and A2A expression is increased on T lymphocytes following activation (17), we hypothesized that A2A blockade would enhance the efficacy of anti–PD-1 by augmenting antitumor T-lymphocyte responses.
Materials and Methods
Cell lines and mice
The C57BL/6 mouse breast carcinoma cell line AT-3 was obtained from Dr. Trina Stewart (Griffith University, Nathan, QLD, Australia; ref. 18), MC38 cells were obtained from Dr. Nicole Haynes (Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia), and 4T1.2 cells were obtained from Prof. Robin Anderson (Peter MacCallum Cancer Centre). Tumor cell lines were transduced to express chicken ovalbumin peptide as previously described (19, 20). These cell lines were originally obtained from the ATCC, actively passaged for less than 6 months, and were authenticated using short tandem repeat profiling. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the use of cell lines in Cancer research were followed. Tumor lines were also verified to be Mycoplasma negative by the Victorian Infectious Diseases References Lab (Melbourne, VIC, Australia) by PCR analysis. Tumor cells were grown in DMEM supplemented with 10% FCS, GlutaMAX, and penicillin/streptomycin. For in vivo experiments, the indicated numbers of cells were resuspended in PBS and injected s.c. in a 100-μL volume. C57BL/6 and BALB/C wild-type (WT) mice were obtained from the Animal Resources Centre (Perth) and the Walter and Eliza Hall Institute of Medical Research (Melbourne, VIC, Australia), OT-I mice, perforin−/−, and IFNγ−/− mice were bred in-house at the Peter MacCallum Cancer Centre, and A2A−/− mice were bred at St. Vincent's Hospital (Melbourne, VIC, Australia).
Vectors and tumor cell transduction
Murine CD73 cDNA (Open Biosystems) was cloned into the pMSCV-Cherry retroviral vector. Retroviruses were made by transfection of either pMSCV-Cherry or pMSCV-Cherry-CD73 in combination with the pMD2.G envelope vector into HEK293gagpol cells using Lipofectamine 2000 (Invitrogen) as per the manufacturer's instructions. AT-3ovadim and MC38ovadim were transduced with pMSCV Cherry-CD73 as previously described (14).
Antibodies, agonists, and antagonists
5′-(N-Ethylcarboxamido)adenosine (NECA) and SCH58261 were purchased from Sigma. mAbs RMP1-14 (anti–PD-1 mAb), 2A3 (Isotype control). and RMT3-23 (anti-TIM-3) were purchased from BioXcell. 145-2C11 (anti-CD3 mAb) used for splenocyte stimulation was purchased from BD Pharmingen and SIINFEKL peptide was purchased from GenScript.
OT-I splenocytes were isolated and labeled with CFSE (1 μmol/L) as per the manufacturer's instructions (eBioscience). CFSE-labeled OT-I splenocytes were cocultured with Mitomycin-treated (5 μmol/L) MC38 ova tumor cells in the presence of SIINFEKL peptide (10 ng/mL). To indicated wells, NECA (1 μmol/L), SCH58261 (1 μmol/L), anti–PD-1 (50 μg/mL), or 2A3 isotype control were added. After 4 days, supernatants were taken for analysis of cytokine content and cells were analyzed by flow cytometry for CFSE dilution, expression of Granzyme B, and T-cell activation markers.
Analysis of adenosine receptor expression by RT-PCR
RNA was isolated from T lymphocytes using the Qiagen RNAEasy Mini Kit as per the manufacturer's instructions. To generate cDNA, mRNA was added to 1 μL of oligo dT and incubated at 65°C for 5 minutes. RNA was then added to a mixture of 4 μL 5× cDNA synthesis buffer (Promega), 2 μL 10 nmol/L dNTP mix (Promega), 1 μL 0.1 mol/L DTT (Promega), 1 μL RNase inhibitor (Promega), 1 μL Reverse Transcriptase (Promega), and 1 μL RNAase free H2O. cDNA was generated at 50°C for 50 minutes and 85°C for 5 minutes before storage at −20°C until analysis of mRNA expression by qRT-PCR. Adenosine receptor expression was determined using the TaqMan Gene Expression Master Mix and primers for A2A and A2B as previously described (9). qRT-PCR for L32 and IFNγ was conducted with SYBR Green (Agilent) as per the manufacturer's instructions using the following primers: L32 forward: TTCCTGGTCCACAATGTCAAG, L32 reverse: TGTGAGCGATCTCAGCAC. IFNγ forward: GCAACAGCAAGGCGAAAAAG and IFNγ reverse: AGCTCATTGAATGCTTGGCG.
Analysis of tumor-infiltrating immune subsets
After euthanizing mice, tumors were excised and digested using a mix of 1 mg/mL collagenase type IV (Sigma-Aldrich) and 0.02 mg/mL DNAase (Sigma-Aldrich). After 30 minutes digestion at 37°C, cells were twice passed through a 70-μm filter. Single-cell suspensions were then prepared and analyzed by flow cytometry as previously described (14). IFNγ and Granzyme B expression was determined directly ex vivo using antibody clones XMG1.2 and GB11, respectively.
Determination of cAMP content of human PBMCs
PBMCs from a normal donor were isolated using Ficoll and cultured for 10 days in IMDM medium (Life Technologies) containing 30 ng/mL of OKT3 (eBioscience) and 500 U of recombinant human IL2 (Prometheus Laboratories). Activated PBMCs were resuspended in serum-free IMDM containing 500 μmol/L IBMX (Sigma) and 100 μmol/L Ro 20-1724 (Sigma) to block phosphodiesterases. SYN115 at 10 μmol/L was added to the cells 15 minutes before the addition of the A2A selective agonist CGS21680 (1 μmol/L). Cells were incubated with the compounds for 1 hour at 37°C and cAMP production was assayed using the cAMP Glo kit (Promega), according to the manufacturer's instructions.
Statistical differences were analyzed by the Mann–Whitney test with P < 0.05 considered statistically significant.
Combination treatment with anti–PD-1 and A2A blockade enhances the IFNγ production of CD8+ T cells in vitro
To explore the link between the A2A and PD-1 suppressive pathways, we first assessed the in vitro effector functions of ova-specific CD8+ OT-I cells when in coculture with MC38ovadim tumor cells and SIINFEKL peptide (10 nmol/L). SIINFEKL peptide was added to the cultures because robust activation of naïve OT-I cells was not observed in the absence of SIINFEKL peptide. Cocultures were performed in the presence or absence of the adenosine analogue NECA (1 μmol/L), the A2A receptor antagonist SCH58261 (1 μmol/L), anti–PD-1 mAb (50 μg/mL), and/or isotype control (2A3). In the presence of NECA, the combination of anti–PD-1 and SCH58261 significantly enhanced IFNγ production (P < 0.05) when compared with single treatment with either agent (Fig. 1A). In the absence of exogenous NECA, neither single nor dual blockade of A2A and PD-1 significantly enhanced IFNγ levels, indicating that in this assay exogenous adenosine (NECA) was required (Supplementary Fig. S1A). In contrast to the effects on IFNγ production, neither anti–PD-1 nor SCH58261 had a significant effect on proliferation as measured by CFSE dilution in this setting (Fig. 1B). The effect of A2A and PD-1 blockade on the cytotoxic activity of OT-I T cells was also investigated. Although it was observed that NECA showed a trend to decrease the expression of Granzyme B by CD8+ OT-I cells, and that Granzyme B expression could be significantly enhanced by the addition of either SCH58261 or anti–PD-1, there was no further increase in Granzyme B expression following dual PD-1 and A2A blockade (Supplementary Fig. S1B). Furthermore, the cytotoxic activity of OT-I cells against MC38ovadim tumor cells following either A2A or PD-1 blockade as measured by 51Cr release or CD107a staining was not modulated (Supplementary Fig. S1C and S1D). Taken together, these data indicate that combined blockade of A2A and PD-1 has the capacity to enhance IFNγ production by CD8+ T lymphocytes in the presence of the adenosine analogue NECA and led us to evaluate this combination therapy in vivo.
A2A blockade enhances the efficacy of anti–PD-1 mAb against CD73+ tumors
Because we hypothesized that adenosine may limit the efficacy of PD-1 blockade, we investigated whether the expression of CD73 by tumor cells rendered them more resistant to anti–PD-1 mAb. CD73 was ectopically expressed in the breast carcinoma cell line AT-3ovadim and the colon carcinoma MC38ovadim (Supplementary Fig. S2A). Although both tumor lines expressed A2B, and to a lesser extent, A1 receptors, the expression of A2A was very low on AT-3 ovadim tumor cells and undetectable on MC38 ovadim tumor cells (Supplementary Fig. S2B). Furthermore, exposure of these tumor lines to NECA in vitro did not modulate their proliferation (Supplementary Fig. S3A) or phenotype, including expression of PD-L1 (Supplementary Fig. S3B). Taken together, this suggests that any effect of A2A blockade would be mediated by modulation of the tumor microenvironment rather than tumor cells themselves.
Tumors were injected s.c. into mice and treated at day 14 once they were established (20–50 mm2). Treatment of AT-3ovadim tumors with anti–PD-1 mAb resulted in a profound and significant reduction in primary tumor growth (Fig. 2A) with a mean reduction in tumor size at day 14 after therapy of 81% (Fig. 2B). However, the efficacy of anti–PD-1 mAb against AT-3ovadim CD73+ tumors was significantly less than against AT-3ovadim control tumors, with a mean reduction of tumor size of only 31% (Fig. 2B). These data thus show that the expression of CD73 reduced the efficacy of anti–PD-1 mAb single-agent therapy.
We hypothesized that the increased resistance of AT-3ovadim CD73+ tumors to anti–PD-1 monotherapy was due to A2A-mediated suppression of antitumor immune responses induced by anti–PD-1 mAb. To investigate this possibility, we determined whether treatment of mice with the A2A antagonist SCH58261 could enhance the therapeutic efficacy of anti–PD-1. Although A2A blockade alone had no effect on the growth of AT-3ovadim CD73+ tumors as a single therapy (Fig. 2A), it significantly enhanced the efficacy of anti–PD-1 mAb in reducing the growth of AT-3ovadim CD73+ tumors (Fig. 2A). The combination of anti–PD-1 and SCH58261 (median survival, 40 days) also significantly increased the survival of mice compared with both isotype control/vehicle–treated mice and anti–PD-1/vehicle–treated mice (median survival, 28 and 34 days, respectively; Fig. 2C). To extend these observations to another tumor model, we also compared the efficacy of anti–PD-1 mAb against established MC-38ovadim and MC38ovadim CD73+ tumors. Similarly as with the AT-3ovadim tumors, CD73 expression on MC38ovadim tumor cells reduced the efficacy of anti–PD-1 mAb treatment (Fig. 2D). Furthermore, as with AT-3ovadim CD73+ tumors, the resistance of MC38ovadim CD73+ tumors to PD-1 blockade was overcome when anti–PD-1 was given in combination with SCH58261 (Fig. 2D). This result indicated that A2A blockade could enhance the efficacy of anti–PD-1 mAb in two distinct tumor models. To confirm that the A2A antagonist SCH58261 was acting through host A2A receptors, we determined the efficacy of anti–PD-1 mAb in WT and A2A−/− mice. Indeed, anti–PD-1 mAb therapy had significantly increased efficacy in A2A−/− mice in terms of both primary tumor growth and survival (Fig. 2E), confirming the importance of host A2A receptors in limiting the antitumor immune response induced by PD-1 blockade.
Having clearly demonstrated that the combination of PD-1 and A2A blockade could treat established primary tumors, we next investigated the ability of this combination to treat the less immunogenic 4T1.2 tumor cell line. To examine this, we injected the 4T1.2 breast cancer line, which expresses CD73 endogenously, into the fourth mammary fat pad of WT mice. Mice were treated with either isotype control (2A3) or anti–PD-1 and SCH58261 or vehicle control. The combination of anti–PD-1 and SCH58261 was ineffective in reducing the primary tumor growth of 4T1.2 tumors (Fig. 3A), perhaps attributable to the low level of PD-1 expression on T cells in this tumor model (Supplementary Fig. S4), and therefore reflecting the lower immunogenicity of this tumor line. However, the combination of anti–PD-1 and SCH58261 significantly reduced the number of spontaneous metastases in this setting (Fig. 3B). We next investigated the ability of anti–PD-1 and SCH58261 to treat established 4T1.2 lung metastases. 4T1.2 tumor cells were injected i.v., and after 3 days, mice were treated with a combination of anti–PD-1 or 2A3 isotype control mAb and SCH58261 or vehicle control. Neither anti–PD-1 nor SCH58261 was effective in reducing the number of metastases when given as a single agent (Fig. 3C). When anti–PD-1 mAb and SCH58261 were given in combination, there was a trend toward a reduction in metastases although this did not reach statistical significance.
It has previously been reported that CD8+ T cells coexpress PD-1 and TIM-3 in the 4T1 breast cancer model and that anti-TIM-3 can significantly enhance the efficacy of PD-1 blockade (21). We therefore hypothesized that the inclusion of anti-TIM-3 in the treatment regimen may liberate antitumor T-cell responses sufficiently for A2A blockade to become effective. Indeed, while anti–PD-1 and anti-TIM-3 showed a trend to reduce the number of tumor metastases, only the inclusion of A2A blockade along with anti–PD-1 and anti-TIM-3 resulted in a significant reduction of tumor metastases (Fig. 3C). The combination of anti-TIM3 and SCH58261 had no significant effect on tumor metastases in the absence of anti–PD-1 (Fig. 3D), indicating that the blockade of multiple immunosuppressive pathways was required for the eradication of established 4T1.2 tumor metastases. Taken together, these data highlight the ability of A2A blockade to enhance the efficacy of checkpoint blockade.
PD-1 blockade enhances A2A expression on CD8+ tumor-infiltrating lymphocytes
Because A2A expression is known to be increased following T-cell receptor (TCR) stimulation and PD-1 ligation is known to dampen TCR signaling (17, 22), we hypothesized that PD-1 blockade may increase A2A expression on T lymphocytes and thus make them more susceptible to A2A-mediated immunosuppression. To investigate this possibility, the expression of A2A on OT-I splenocytes cocultured with (PD-L1 expressing) MC38ovadim tumor cells in vitro was examined in the presence or absence of PD-1 blockade. A2A expression was determined by qRT-PCR due to the lack of an antibody specific for the A2A receptor suitable for flow cytometry. The expression of IFNγ was used as a positive control because it has previously been shown that PD-1 blockade enhances IFNγ production (23). As expected, PD-1 blockade significantly increased the expression of IFNγ by CD8+ OT-I cells cocultured with MC38ovadim tumor cells (Fig. 4A). Notably, PD-1 blockade also significantly enhanced the expression of A2A receptors on CD8+ OT-I cells compared with CD8+ OT-I cells treated with an isotype control antibody (Fig. 4B). To investigate whether A2A upregulation following PD-1 blockade also occurred in vivo, CD8+ and CD4+ T cells were isolated from AT-3ovadim CD73+ tumors following treatment of mice with either anti–PD-1 or isotype control mAb. Notably, CD8+ T cells isolated from tumors of mice treated with anti–PD-1 had significantly elevated expression of both IFNγ and the A2A receptor compared with those isolated from isotype control–treated mice (Fig. 4C). Furthermore, isolation of the CD8+PD-1hi and CD8+PD-1low subsets revealed that the PD-1hi population had significantly elevated expression of A2A compared with PD-1low counterparts (Fig. 4D). The increase in A2A expression following PD-1 blockade was restricted to CD8+ T cells from within the tumor microenvironment as CD8+ T cells isolated from spleens and draining lymph nodes displayed no increase in A2A expression (Supplementary Fig. S5A and S5B). In contrast, while CD4+ T cells displayed a trend for increased expression of IFNγ following PD-1 blockade, there was no increase in A2A expression on these cells (Supplementary Fig. S5C). However, because the CD4+ tumor-infiltrating lymphocyte (TIL) population contains a significant proportion of foxp3+ cells (∼50%), the possibility that PD-1 blockade modulates A2A expression on either the foxp3− effector cells or foxp3+ regulatory T cells cannot be discounted.
Taken together, these data indicate that PD-1 blockade enhances the expression of A2A receptors on tumor-infiltrating CD8+ T cells and therefore increases their susceptibility to adenosine-mediated immunosuppression. These data may explain why A2A blockade enhances the antitumor efficacy of anti–PD-1 but has little impact on the primary growth of AT-3ovadim CD73+ tumor cells when administered as a single therapy (Fig. 2).
Combination of PD-1 and A2A blockade significantly enhances the IFNγ production of tumor-infiltrating CD8+ T lymphocytes
To characterize the mechanism by which A2A blockade enhanced the efficacy of PD-1 mAb in vivo, the number and phenotype of TILs were investigated in mice bearing AT-3ovadim CD73+ tumors treated with either an isotype control antibody (2A3) or anti–PD-1 mAb and either SCH58261 or vehicle control. TILs were analyzed at days 1, 2, and 7 after treatment. Although the proportion of TCRβ+CD8+, TCRβ+CD4+foxp3−, and TCRβ+CD4+foxp3+ TILs was not modulated by either anti–PD-1 alone or in combination with A2A blockade (Supplementary Fig. S6A–S6C), we observed that the combination therapy significantly enhanced CD8+ T-cell effector functions. Analysis of TILs at day 1 showed that treatment with anti–PD-1 significantly increased the expression of IFNγ and Granzyme B by CD8+ TILs, which was not further enhanced following combination treatment with SCH58261 (Fig. 5A). However, 2 days following treatment, a significantly higher proportion of the CD8+ T cells isolated from mice treated with the combination therapy were IFNγ+ and Granzyme B+ compared with those isolated from mice treated with anti–PD-1 mAb alone (Fig. 5A and B). The trend toward increased IFNγ production by CD8+ TILs in the combination group extended to day 7 after therapy with only the combination therapy giving a significantly enhanced proportion of IFNγ+ CD8+ TILs compared with isotype control/vehicle–treated mice (Supplementary Fig. S7). Thus, although the initial response to anti–PD-1 mAb was not affected by A2A blockade, the induced CD8+ T-cell response was maintained by the A2A antagonist SCH58261. In contrast, no increased expression of IFNγ was seen on CD4+ TILs following either anti–PD-1 mAb single-agent therapy or anti–PD-1 mAb/SCH58261 combination therapy at either time point (Supplementary Fig. S8A). We also investigated the effect of A2A blockade on the expression of PD-1 on TILs. SCH58261 had no significant effect on PD-1 expression either in combination with PD-1 blockade (Supplementary Fig. S6) or on its own (Supplementary Fig. S9A). Moreover, A2A blockade did not affect the expression of PD-L1 on tumor cells (Supplementary Fig. S9B), further suggesting that the efficacy of PD-1/A2A blockade was due to enhanced T-cell effector function.
To further investigate the CD8+ T-cell populations modulated by the combination therapy, we analyzed IFNγ production and Granzyme B expression of the CD8+PD-1hi cells and CD8+PD-1low cells. Interestingly, dual anti–PD-1 mAb and SCH58261 treatment significantly increased the expression of IFNγ in both the CD8+PD-1hi and CD8+PD-1low subsets compared with anti–PD-1 alone (Fig. 5C). In contrast, Granzyme B expression was more selectively modulated by the combination therapy in the CD8+PD-1hi population (Supplementary Fig. S8B). As with the analysis of the global CD8+ TIL population (Fig. 5A), the increase in IFNγ production by the CD8+PD-1hi cells following combination therapy was seen at day 2 (Fig. 5C) but not at day 1 (Supplementary Fig. S8C), indicating that A2A blockade maintained the activation induced by anti–PD-1 mAb.
We next investigated whether the antigen-specific CD8+ T-cell population was modulated by anti–PD-1 mAb/SCH58261 treatment. Although PD-1 blockade enhanced the proportion of CD8+ TILs that were ova tetramer specific, the addition of the A2A antagonist did not further enhance this effect (Supplementary Fig. S8D). Notably, however, a significantly higher proportion of these ova tetramer+ TILs expressed IFNγ when isolated from anti–PD-1/SCH58261-treated mice compared with mice treated with anti–PD-1 mAb alone (Fig. 5D). No increase in IFNγ or Granzyme B was observed within CD8+ TILs in mice treated with SCH58261 in the absence of anti–PD-1, confirming that the combination of PD-1 and A2A blockade was required for this effect (Supplementary Fig. S9C and S9D). Taken together, these data indicate that the enhanced efficacy of anti–PD-1 mAb/SCH58261 treatment was due to enhanced effector function of TILs as opposed to increased proliferation and/or recruitment. To determine the functional importance of increased IFNγ secretion and Granzyme B expression in terms of the antitumor immune response induced by the combination of anti–PD-1 mAb and SCH58261, the efficacy of this combination therapy was determined in IFNγ−/− and perforin−/− mice. The effectiveness of anti–PD-1 mAb/SCH58261 was completely abrogated in IFNγ−/− mice but not perforin−/− mice, indicating that the increased IFNγ production induced by the combination of SCH58261 and anti–PD-1 mAb was critical for its improved efficacy (Fig. 6).
Enhancement of anti–PD-1 function with the clinical trial drug SYN115
To enhance the translational relevance of our study, we also assessed the potential of SYN115, an A2A antagonist that has undergone phase IIb clinical trials (16), to enhance anti–PD-1 function. Established AT-3ovadim CD73+ tumors were treated with an isotype control or anti–PD-1 mAb in combination with either SCH58261, SYN115, or vehicle. We observed that SYN115 had no single-agent activity, but significantly enhanced the antitumor efficacy of anti–PD-1 mAb (Fig. 7A) to a similar extent as SCH58261 (Fig. 7B). SYN115 was also able to significantly inhibit the increased cAMP concentrations mediated by the specific A2A agonist CGS21680 on activated human PBMCs (Fig. 7C). Thus, an A2A antagonist known to be safe and well tolerated in patients can enhance the antitumor efficacy of anti–PD-1 mAb, underlining the potential of this combination therapy to be translated into the clinic.
It is increasingly recognized that immunotherapy is an effective strategy in several cancer types. In particular, recent results from clinical trials indicate that PD-1 blockade is a powerful emerging immunotherapeutic strategy (2). However, the success of anti–PD-1 therapy is limited to a subset of patients and thus further work is required to enhance the therapeutic benefit of anti–PD-1 and improve our understanding of where PD-1 blockade is most likely to provide patient benefit. For example, the success rate of PD-1 blockade can be improved if patients are selected on the basis of their tumors expressing the PD-1 ligand PD-L1 (2, 24).
The identification of additional biomarkers that are predicative of the response to anti–PD-1 mAb would be an important advance in our understanding, especially considering the prohibitive expense of immunotherapy. We have previously reported that CD73 is a negative prognostic marker for triple-negative breast cancer and predictive of a poor objective response to anthracycline therapy (8). Herein, we describe data indicating that the expression of CD73 by tumor cells also significantly reduces the efficacy of anti–PD-1 and that this can be overcome with blockade of A2A receptors. We focused on the ability of A2A blockade to enhance the efficacy of anti–PD-1 mAb because A2A is upregulated on T cells following activation (17) and has an affinity for adenosine approximately 1,000-fold greater than that of A2B. However, the blockade of other adenosine receptors such as A2B may also enhance the therapeutic efficacy of anti–PD-1 either directly or through indirect mechanisms such as the modulation of dendritic cells (12) or myeloid-derived suppressor cells (25).
Because we have shown that the CD73:A2A pathway can limit the efficacy of anti–PD-1 therapy, it would be interesting to evaluate whether CD73 is a biomarker for the clinical responses to anti–PD-1 mAb therapy in patients. Recently, a phase I study reported that combining CTLA-4 and PD-1 blockade may improve the efficacy of either treatment alone (26). This is further supported by a large body of preclinical data that combining PD-1 blockade with other immunotherapies, including anti-CTLA-4 (27–30), anti-TIM-3 (21), anti-OX40 (31), anti-CD73 (10) anti-CD137 (32), anti-GITR (33), cancer vaccines (29), radiotherapy (34), chemotherapy (32), and adoptive cellular therapy (35), can significantly enhance antitumor immune responses. The results of a recent study suggested that PD-1 blockade could enhance the antimetastatic activity of A2A blockade through enhanced natural killer (NK) cell responses (36). Our data indicate that A2A blockade also enhances the efficacy of anti–PD-1 mAb in a primary tumor setting and warrant further investigation as a combination therapy. In contrast with these authors, however, we found that the enhanced efficacy of PD-1/A2A dual blockade was due to enhanced CD8+ T-cell function and found little expression of PD-1 on NK cells in the 4T1.2 tumor model. If both mechanisms are valid, this suggests that enhanced NK cell function is an indirect consequence of PD-1 blockade. Furthermore, we also show that A2A blockade was able to enhance the efficacy of anti–PD-1 against established 4T1.2 lung metastases only when given in combination with anti-TIM-3. These data highlight that treatment of more established metastatic disease may require blockade of multiple inhibitory pathways.
The efficacy of A2A antagonists when given in combination with anti–PD-1 is likely related to the fact that PD-1 blockade enhances the expression of A2A receptors on tumor antigen–specific CD8+ TILs, therefore making them more susceptible to adenosine-mediated immunosuppression. The mechanism by which PD-1 blockade enhances A2A expression is not known. However, A2A expression is known to be increased in T lymphocytes following TCR activation (17) and PD-1 has been shown to suppress Ca2+ ERK responses immediately downstream of the TCR (22). Therefore, it seems likely that the mechanism by which PD-1 blockade increases A2A expression is a direct consequence of enhanced TCR signaling, at least in part. Indeed, this hypothesis is supported by the fact that upregulation of A2A on antitumor CD8+ T cells was seen both in vitro and in vivo following PD-1 blockade. Furthermore, because our data indicate that A2A is more highly expressed on PD-1+ cells, the blockade of PD-1 may lead to the enrichment of the PD-1+ subset and consequently increase the proportion of CD8+ T cells susceptible to A2A-mediated suppression. In this study, we did not observe that A2A blockade significantly modulated PD-1 expression on CD8+ or CD4+ T cells. Although our observation appears to contrast with the observations of Cekic and Linden (37), the difference may be that in our study A2A blockade was conducted in established tumors in which memory T cells have already differentiated or because the pharmacologic antagonist SCH58261 does not mediate full A2A blockade. Therefore, the timing and magnitude of A2A blockade may be crucial to the therapeutic outcome.
It has been proposed that the additional benefit of combined CTLA-4 and PD-1 blockade is attributable to the fact that PD-1 and CTLA-4 inhibit T-cell activation via distinct signaling pathways (38, 39). This is also the case for A2A blockade. Although PD-1 signaling decreases the phosphorylation of proximal TCR signaling proteins, such as CD3ξ, ZAP70, PI3K, and PKCθ, via the recruitment of SHP-1 and SHP-2 (38–41), A2A activation acts to suppress T cells via enhanced cAMP concentrations. This process results in the activation of PKA, which consequently inhibits the activity of NFAT (42, 43), NFκB (44), and MAPK (45). Therefore, there is a precedent to evaluate the potential benefit of dual A2A and PD-1 blockade in the clinic, especially among the cohort of patients who do not respond well to anti–PD-1 alone.
Although A2A blockade did not enhance either the proportion of CD8+ T cells or the frequency of antigen-specific CD8+ cells, our findings indicate that the combination of PD-1 and A2A blockade was able to significantly increase the production of IFNγ by antitumor T cells both in vitro and in vivo. Interestingly, while anti–PD-1 mAb single therapy was able to induce a similar upregulation of IFNγ on CD8+ cells 24 hours after treatment compared with combination therapy, the combination of A2A blockade and PD-1 blockade resulted in significantly more IFNγ+ cells 48 hours after treatment. This indicates that A2A blockade sustains the anti–PD-1 response and is likely due to the upregulation of A2A receptors on CD8+ TILs following PD-1 blockade. Although the increase in IFNγ production was most marked in the antigen-specific CD8+PD-1hi population, we also observed an increased production of IFNγ in the CD8+PD-1low subset following combination therapy. The reason for this is not known but it is possible that the PD-1low subset is indirectly affected because of proinflammatory cytokines secreted by the PD-1hi cells, leading to increased activation of the PD-1low cells themselves, as well as activation of other immune subsets, including APCs. We observed no increased expression of IFNγ by CD4+ T cells following PD-1 blockade despite expression of PD-1 by these TILs. This may be explained by the fact that CD4+ T cells are less sensitive to PD-1–mediated inhibition than CD8+ T cells (46). However, it should be noted that one caveat with these experiments is that we did not distinguish between foxp3− and foxp3+ cells, which may have skewed our interpretation of these results. Nevertheless, the increased efficacy of PD-1 and A2A blockade, compared with anti–PD-1 mAb alone, seems largely attributable to an increased IFNγ response from CD8+PD-1+ tumor antigen–specific TILs. Indeed, the combination therapy of PD-1/A2A blockade was ineffective in IFNγ−/− mice. These results are consistent with observations by other groups that blockade of other checkpoint inhibitors, such as CTLA-4 or TIM-3 (21, 27, 47), can enhance IFNγ production by CD8+ TILs following anti–PD-1 mAb treatment.
Although our results suggest that the enhanced therapeutic activity of dual PD-1 and A2A blockade is related to enhanced IFNγ responses, we also observed that A2A blockade enhanced the expression of Granzyme B in CD8+ TILs when given in combination with anti–PD-1. Whether this translates to enhanced cytotoxic function is not clear, however, because we observed no evidence of PD-1 or A2A blockade enhancing cytotoxic function of CD8+ T cells in vitro. This discrepancy may be explained by the activation status of the CD8+ T cells used in our in vitro assays because the cells used for typical in vitro “killing assays” are preactivated with high doses of IL2. It is known that activation of CD8+ T cells with IL2 can overcome the suppression mediated by PD-1 (46). Other groups have previously observed enhanced CTL function following PD-1 blockade (48, 49) using different experimental systems. Our experiments with perforin−/− mice show that enhanced cytolytic function is not critical for the efficacy of the combination therapy. Notably, however, although the efficacy of the combination therapy was not abolished in perforin−/− mice, the extent of tumor control appeared to be somewhat reduced in these mice when compared with WT controls. Thus, it remains possible that the efficacy of combination therapy in vivo may also be attributable in part to enhanced cytotoxic T-cell function.
In this study, we provide evidence that CD73 expression is a negative prognostic marker with regard to the therapeutic efficacy of PD-1 blockade and that A2A antagonists may be a viable option to improve the clinical efficacy of anti–PD-1 mAb therapy. Interestingly, it has recently been reported that A2A blockade can also enhance the function of CTLA-4 mAb in a murine melanoma model (50). This suggests that A2A blockade may be able to enhance the clinical efficacy of other checkpoint inhibitors. Several A2A antagonists have undergone clinical trials for Parkinson disease, including istradefylline (KW-6002-phase III), preladenant (SCH-420814 phase II; ref. 15), and SYN-115 (phase IIb; ref. 16), the compound used in our studies. These drugs have thus far been found to be safe and well tolerated, indicating that they could be readily applied to patients with cancer. Therefore, our work using A2A antagonists to block the CD73 pathway carries strong clinical relevance given that no anti-CD73 mAbs are in clinical development. Our studies have revealed a previously unreported function of SYN-115 in enhancing antitumor immunity, underlining the fact that the combination of PD-1 and A2A blockade has immediate translational potential.
Disclosure of Potential Conflicts of Interest
J. Stagg has ownership interest (including patents) and is a consultant/advisory board member for Surface Oncology. No potential conflicts of interest were disclosed by the other authors.
Conception and design: P.A. Beavis, J. Stagg, P.K. Darcy
Development of methodology: P.A. Beavis, N. Milenkovski, P.K. Darcy
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P.A. Beavis, N. Milenkovski, M.A. Henderson, L.B. John, B. Allard, P.K. Darcy
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P.A. Beavis, N. Milenkovski, S. Loi, M.H. Kershaw, P.K. Darcy
Writing, review, and/or revision of the manuscript: P.A. Beavis, N. Milenkovski, M.A. Henderson, B. Allard, S. Loi, J. Stagg, P.K. Darcy
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P.A. Beavis, N. Milenkovski, P.K. Darcy
Study supervision: P.A. Beavis, M.H. Kershaw, J. Stagg, P.K. Darcy
This work was funded by a Project Grant from the National Health and Medical Research Council (NHMRC; 1062580). P.A. Beavis was supported by a National Breast Cancer Fellowship (PF-14-008). P.K. Darcy and M.H. Kershaw were supported by NHMRC Senior Research Fellowships (1041828 and 1058388, respectively). J. Stagg was supported by an Operating Grant (Remodeling of the tumor microenvironment by CD73: a therapeutic target) from the Canadian Institutes of Health Research.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The authors acknowledge the assistance of the Peter MacCallum Cancer Centre Experimental Animal facility technicians for animal care and Dr. Karen Dwyer from St. Vincent's Hospital for provision of the A2A−/− mice.
Note: Supplementary data for this article are available at Cancer Immunology Research Online (http://cancerimmunolres.aacrjournals.org/).
- Received November 11, 2014.
- Revision received January 29, 2015.
- Accepted February 2, 2015.
- ©2015 American Association for Cancer Research.